What is a atopic allergy
If you are love most people, you hate the thought of walking into a crowded waiting room at the doctor’s office – and facing a endless wait before the doctor or nurse practitioner can see you. After every, your time is just as valuable as theirs.
Maybe that’s why thousands of patients own chosen Allergic & Asthmatic Comprehensive Care of New Jersey (AACCNJ).
At AACCNJ, our medical director, Eric S. Applebaum, MD, schedules and sees one patient at a time. That’s how he has done it for over 20 years. Dr.
Applebaum strives to be on time for your scheduled appointment as he also understands the worth of your time.
It’s not unusual for Dr. Applebaum to spend a full hour with each patient, answering their questions, explaining treatment options and simply getting to know them as individuals. He believes that’s the best way to accurately diagnose their conditions and assist them overcome the limitations their allergies and asthma put upon them.
Applebaum provides comprehensive care for the full spectrum of allergy and asthma conditions and symptoms, including:
• Food allergies • Seasonal allergies • Pollen allergy • Atopic dermatitis • Eczema • Skin rash • Hives
• Allergic rhinitis (hay fever) • Chronic sinusitis • Nasal congestion • Asthma • Coughing • Wheezing
AACCNJ serves the Mountain Lakes and Parsippany Troy Hills communities of Parsippany, Denville, Montville (Morris County, NJ), Passaic (Passaic County, NJ).
Discover today’s most effective allergy and asthma treatment.
Believe Eric S. Applebaum, MD, for comprehensive allergy, asthma and immunology care and advanced solutions. Call us at 973.335.1700 in Parsippany or use our online Request an Appointment form to schedule your consultation.
S. aureus: the bacterial culprit that drives atopic dermatitis (National Eczema Association)
The relationship between atopic dermatitis and Staphylococcus aureus is longstanding and complicated. A Dutch company is investing in a new technology that targets staph to assist reduce disease severity.
Approximately 1,000 species of bacteria live on the surface of the skin, but available data suggests one plays an outsized role in atopic dermatitis (AD):Staphylococcus aureus(staph).
A Polish research team recently published a review article in the February 2019 issue of Advances in Dermatology and Allergology that evaluated the findings of a large number of studies on the complicated relationship between staph and AD.
When cultured during an eczema flare, staph overgrowth is seen in the inflamed skin of 90% of eczema patients.
What has been unclear is whether the bacterium actually causes an AD flare or simply takes advantage of the favorable environment — the dry, cracked skin that is the hallmark of eczema — to set up store and cause trouble.
The researchers lean toward the previous view based on evidence gathered during their review of the literature.
First, staph tends to crowd out the friendly bacterial species, called commensals, that provide the balance and diversity necessary to a healthy microbiome.
The researchers see staph as a likely suspect in causing the unstable skin microbiome that is characteristic of AD.
Second, staph creates every kinds of problematic byproducts that interfere with the immune system’s ability to mount a normal response — another hallmark of AD.
Among these by-products is biofilm, a slimy matrix in which bacteria can hide, thrive and evade attack by immune cells that would normally be capable to clear the infection. The chronic skin damage seen in AD offers a perfect setting for biofilm formation, the researchers said.
Staph also secretes enzymes that assist allergens penetrate the skin and superantigens that provoke an unusually large inflammatory response.
Despite the potential for staph to exert these negative effects, the co-authors warned against antibiotics as a routine treatment for AD, primarily because of concerns around antibiotic resistance, but also because of the chronic nature of AD.
Keeping an AD patient on antibiotics over endless periods of time is inappropriate and ultimately harmful, they wrote.
With the shortage of effective antimicrobial treatments and the rise of resistant strains of staph — among other virulent species — the search is on for alternatives to antibiotics.
Enter endolysin technology.
While antibiotics work by interfering with essential bacterial structures and processes or thwarting their ability to reproduce, the endolysin approach relies on viruses to do the job.
Endolysins are enzymes produced by viruses, called bacteriophages, that infect bacteria. These viruses latch on to the bacterium’s cell wall and inject their DNA inside it. That’s how the viruses reproduce.
To assist new bacteriophages emerge, the endolytic enzyme breaks the bacterial cell wall open and kills the bacterium in the process.
A Dutch company (Micreos) has been investing in this new technology, recently launching its over-the-counter topical eczema product, Gladskin.
The product’s key ingredient is Staphefekt, the company’s version of an endolytic enzyme, which specifically targets staph.
Gladskin also aims to restore the balance of the skin microbiome and ease the symptoms of eczema across the spectrum of disease severity.
Because of its unique mechanism of action, bacterial resistance should not be a problem, the manufacturer said, and researchers in the fields of immunology and microbiology consent with that claim.
Time will tell if the new technology takes hold and ultimately replaces traditional antibiotics. For now, it’s a trend that’s worth watching.
- American Board of Allergy and Immunology
- American Board of Pediatrics
- Residency: University of South Carolina, Palmetto Health Richland Children’s Hospital
- Medical School: Medical College of Georgia
- Fellowship: Vanderbilt University, Allergy/Immunology
- College: University of Kansas, B.A., Psychology
Nicole Chadha received her B.A. in psychology from the University of Kansas, then returned to her southern roots in Georgia to pursue her career in medicine. She graduated with her medical degree from the Medical College of Georgia in Augusta, GA. She subsequently completed her pediatric residency at Palmetto Health Richland Children’s Hospital associated with the University of South Carolina and fellowship in Allergy/Immunology at Vanderbilt University.
Upon completion of her fellowship, Dr. Chadha remained on faculty at Vanderbilt as an Assistant Professor within the Division of Pediatric Allergy, Immunology, and Pulmonary Medicine.
Dr. Chadha is board certified in Pediatrics and Allergy and Immunology.
She is a member of the American Academy of Allergy, Asthma, and Immunology, and the American College of Asthma Allergy and Immunology.
Dr. Chadha chose to specialize in Allergy in specific because she enjoys studying the intricacies of the immune system and likes that the specialty allows her to treat both children and adults. The chronic nature of allergic disease affords her the chance to build lasting relationships with her patients. She finds grand reward in providing care and education that results in an improved quality of life for her patients.
Dr. Chadha has numerous interests in a variety of allergic and immunologic conditions, including food allergy, asthma, urticaria, allergic rhinitis, primary immunodeficiency and eosinophilic esophagitis. She has contributed to research on eosinophilic esophagitis in children and has presented her work both locally and nationally.
Dr. Chadha lives in Charlotte with her husband, Ashley, a pediatric pulmonologist, 2 young sons, and 2 dogs.
In her free time, she enjoys traveling, reading, cooking, interior design, volunteering and taking part in community events.
Schedule an Appointment
To schedule or update an appointment and general questions, please call…
Or Contact Us
Please note: Due to healthcare privacy laws, we cannot answer any questions pertaining to personal health information by e-mail.